Impella CP percutaneous left ventricular support is widely used in cardiogenic shock and high-risk PCI, though limited randomized evidence supports its benefits amidst growing complication concerns.
This review highlights the principles and current evidence for Impella CP use in cardiogenic shock and high-risk PCI, emphasizing the need for more randomized data given concerns over complication rates.
The Impella (Abiomed, Danvers, MA, USA) microaxial pump is a percutaneous mechanical circulatory support (MCS) that has been shown to increase coronary perfusion, reduce myocardial oxygen demand, and improve peripheral organ perfusion. Therefore, indications for the Impella device include emergency use for cardiogenic shock (CS) and pre-emptive implantation during high-risk percutaneous coronary intervention (HR-PCI). However, despite their exponential use in cardiovascular practice over the past decade, there is limited randomized evidence to support the benefits of this therapy and growing concern regarding complication rates. In this review, we summarize the principles, evidence, and practical considerations of the most widely used Impella CP percutaneous left ventricular support in both CS and HR-PCI settings, moving from the historical background to current issues and future expectations for this device.
Masiero et al. (Tue,) conducted a review in Cardiogenic shock and high-risk percutaneous coronary intervention. Impella CP percutaneous left ventricular support was evaluated. Impella CP percutaneous left ventricular support is widely used in cardiogenic shock and high-risk PCI, though limited randomized evidence supports its benefits amidst growing complication concerns.